Building a portfolio you can actually hold for 10 years is harder than it sounds. The temptation to trade is constant, and most names that look like obvious holds today either stagnate, get disrupted, or cut their dividend within a decade.
The narrow group that consistently survives a full cycle and keeps paying shareholders is the Dividend Aristocrats, S&P 500 companies that have raised their dividend every year for at least 25 consecutive years. The list runs about 65 names, but only a handful combine reliable income, defensive cash flow, and a durable moat.
The five below are the core of a 10-year dividend hold. They are not the highest-yielding names available, and they are not going to lead a bull market. They are designed to compound through one.
What a 10-Year Hold Demands From a Dividend Stock
Three things separate a 10-year hold from a 10-month one.
- First, dividend coverage: free cash flow should comfortably exceed the dividend, with a payout ratio under 70 percent.
- Second, balance sheet discipline: net debt to EBITDA below 3x is the rough threshold where a recession does not force a cut.
- Third, brand or category moat: the business should sell something the consumer pays for in good times and bad.
Coca-Cola is iconic on all three. So is Procter & Gamble. Pharma names like AbbVie are different: their moat comes from the patent portfolio and the pipeline, so evaluation requires looking past the current biggest drug.
The framework is laid out in our dividend investing strategy guide, and the S&P Dividend Aristocrats list is the standard reference.
Coca-Cola (KO): Brand Moat and a 60-Year Streak
Coca-Cola (KO) has raised its dividend for over 60 consecutive years and today owns roughly 200 brands across non-alcoholic beverages. The yield typically sits between 2.8 and 3.2 percent, modest compared to higher-yield names but supported by extremely defensive cash flow.
- The bear case is that consumer preference for sugar-heavy beverages has eroded for two decades and the company has had to acquire its way into water, energy drinks, and ready-to-drink coffee.
- The bull case is that the global distribution network is essentially impossible to replicate, even as the underlying products evolve.
Johnson & Johnson (JNJ) and Procter & Gamble (PG): Defensive Compounders
Johnson & Johnson (JNJ) is now a pure-play pharma and medical device company after spinning off its consumer health business as Kenvue in 2023. The dividend has been raised every year for over 60 years.
The medical device franchise (orthopedics, surgery, vision) is the boring but durable core, and the pharma pipeline includes oncology, immunology, and neuroscience exposures that diversify revenue across patent cycles.
Procter & Gamble (PG) sells the products that show up in nearly every middle-class American home: Tide, Pampers, Gillette, Crest, Charmin. The brand stable creates pricing power, and management has been disciplined about portfolio pruning since 2014.
PG and JNJ are both core defensive holdings, with payout ratios in the 50 to 60 percent range and dividend coverage that has held through every major US recession in the past four decades.
3M (MMM) and AbbVie (ABBV): Yield Plus Recovery
3M (MMM) is the dividend story with the most upside if the recovery thesis works. The company has spent the past three years digesting earplug litigation, environmental settlements, and the Solventum healthcare spin-off.
The yield has compressed from a peak above 6 percent but remains attractive relative to the long-term average. Buyers today are paying for the post-litigation operating business, which is more focused than at any point in the past decade.
AbbVie (ABBV) faces the post-Humira patent cliff, but Skyrizi and Rinvoq combined are now generating more revenue than Humira ever did.
The dividend has grown every year since the 2013 spin-off from Abbott, and the yield typically sits in the 3.5 to 4 percent range. AbbVie's replacement-pipeline execution is one of the more underappreciated stories in US large-cap pharma.
Building the 5-Stock Basket
An equal-weighted basket of KO, JNJ, PG, MMM, and ABBV produces a blended yield around 3.5 percent, sector exposure split between consumer staples, healthcare, and industrials, and a beta well below 1.
Hold each at 20 percent of the dividend allocation and rebalance once a year if any single name drifts above 30 percent of the basket. None of these are growth stocks. They compound 7 to 9 percent annually over a decade through reinvested dividends and modest earnings growth.
Conclusion
A 10-year dividend hold is not about chasing the highest yield on the screen. It is about owning businesses with the cash flow, the balance sheet, and the moat to survive the next two recessions. KO, JNJ, PG, MMM, and ABBV are the boring core that lets you hold equities through volatility, collect a rising income stream, and let compounding do the work.
To start your dividend basket, look at all five tickers in the Gotrade app, set a recurring buy schedule, and reinvest the dividends.
FAQ
Are these dividend stocks safe in a recession?
The five names selected here have all maintained or raised dividends through the 2008 and 2020 recessions, though no equity is fully safe in extreme drawdowns.
What yield should I expect from this basket?
The blended yield typically sits in the 3.0 to 3.8 percent range, depending on entry prices and individual dividend changes.
Should I reinvest the dividends?
For a 10-year hold, yes. Dividend reinvestment is what turns a 3.5 percent yield into roughly half of the total return over a decade.
Is 5 stocks enough diversification?
Inside a broader portfolio that already holds index ETFs, yes. As a standalone portfolio, no. Treat this basket as a defensive sleeve, not a complete portfolio.
